Document:

Exhibit 4.24

 

This letter sets out the main terms upon which you serve as a non-executive director of Coca-Coca HBC AG (the “Company”). It is agreed that this letter constitutes a contract for services (mandate pursuant to art. 394 ff. of the Swiss Code of Obligations (“Swiss CO”)) and is not a contract of employment. The terms of this letter take effect on and from [·], the date of your election.

 

1                              Definitions and Interpretation

 

1.1                    In this letter:

 

(a)                       “Admission and Disclosure Standards” means the Admission and Disclosure Standards of the London Stock Exchange plc (as amended from time to time);

 

(b)                       “AGM” means the annual general meeting of the Company;

 

(c)                        “Articles” means the articles of association of the Company as amended from time to time;

 

(d)                       “Board” means the board of directors of the Company from time to time;

 

(e)                        “Corporate Governance Code” means the UK Corporate Governance Code issued from time to time by the UK Financial Reporting Council;

 

(f)                         “DTRs” means the rules relating to the disclosure of information made in accordance with Part VI of FSMA;

 

(g)                        “EGM” means an extraordinary general meeting of the Company;

 

(h)                       “FSMA” means the Financial Services and Markets Act 2000 (as amended from time to time);

 

(i)                           “Group Company” means any company or other legal entity controlled directly or indirectly by the Company;

 

(j)                          “Guidance” means the Guidance on Board Effectiveness issued by the UK Financial Reporting Council;

 

(k)                       “Listing Rules” means the listing rules made by the UK Financial Conduct Authority under Part VI of FSMA;

 

(l)                           “Minder Amendments” means the Swiss Ordinance Against Excessive Compensation in Listed Companies issued by the Federal Council which was implemented based on the so-called “Minder” amendment to the Swiss Federal Constitution (such implementing rules, once they enter into force, including any successor law enacted by the Swiss Parliament from time to time);

 

(m)                   “Model Code” is as defined in the Listing Rules;

 

(n)                       “Organisational Regulations” means Company’s organisational regulations (including its annexes) as amended from time to time;

 

(o)                       “Prospectus Rules” means the Prospectus Rules published by the UK Financial Conduct Authority under Part VI of FSMA; and

 

(p)                       “Remuneration Policy” means the remuneration policy adopted by the Company’s remuneration committee and, if applicable, as approved by the Company’s shareholders from time to time.

 

 

1.2                    A reference to any statute or statutory provision shall include any orders, regulations or other subordinate legislation made under it and any statutory modification or re-enactment of it for the time being in force.  The term “including” shall mean “including but not limited to”.

 

2                              Appointment

 

2.1                    Subject to the remaining provisions of this letter, early dismissal by a shareholders’ vote or your resignation after giving to the Board not less than 6 months’ notice in writing, your appointment shall be for an initial period of one year from the date of your election.  For the purposes of this paragraph 2.1, one year shall refer to the time period between two AGMs or, if your election is at an EGM, to the time period between the EGM and the next AGM.  Non-executive directors are typically expected to serve six one-year terms; however this is subject to your confirmation and then subsequent annual re-election by the Company’s shareholders. The continuation of your appointment by the Company is contingent on your continued satisfactory performance, re-election by shareholders and any relevant statutory provisions relating to the removal of a director. Notwithstanding any mutual expectation, there is no right to re-nomination by the Board.

 

2.2                    Your appointment is subject to the Articles and applicable law. Nothing in this letter shall be taken to exclude or vary the terms of the Articles as they apply to you as a director of the Company. The Articles, in compliance with the provisions of the Corporate Governance Code and the Minder Amendments, require all directors to seek re-election at each AGM. If the shareholders do not confirm your appointment or re-elect you as a director in accordance with the Articles and applicable law, or if you are dismissed by a shareholders’ vote, your appointment shall terminate automatically and with immediate effect and without compensation.

 

2.3                    Notwithstanding paragraphs 2.1 and 2.2, the Board, may suspend you from office with immediate effect and without compensation if you have:

 

(a)                        committed a material breach of your obligations under this letter;

 

(b)                       committed any serious or repeated breach or non-observance of your obligations to the Company (which include an obligation not to breach your fiduciary duties under Swiss law);

 

(c)                        been guilty of any fraud or dishonesty or acted in any manner which, in the opinion of the  Board, brings or is likely to bring you or the Company into disrepute or is materially adverse to the interests of the Company; or

 

(d)                       been declared bankrupt or have made a court-administered arrangement with or for the benefit of your creditors under any applicable bankruptcy laws; or

 

(e)                        been disqualified from acting as a director; or

 

(f)                         become incapable of acting, in part or in full, as a result of an administrative or court order, or otherwise become incapable, in the opinion of the Board (acting reasonably), of properly performing your duties under this letter; or

 

(g)                        been convicted of any arrestable (or equivalent) criminal offence (other than an offence under the road traffic legislation in any jurisdiction for which non-custodial penalties are imposed); or

 

(h)                       been in breach of the Model Code, or any other share dealing code adopted by or relevant to the Company; or

 

2

 

(i)                           not complied with the Company’s anti-corruption and bribery policy and procedures or the UK Bribery Act 2010.

 

2.4                    On suspension of office, you shall at the request of the Board resign from your office as a director of the Company and all offices held by you in any Group Company.

 

2.5                    The relationship between you and the Company shall be that of office-holder and not one of employment.

 

2.6                    The Board has determined you to be independent according to the Organisational Regulations and the provisions of the Corporate Governance Code.

 

3                              Role and Duties

 

3.1                    You shall carry out the function of a non-executive director of the Board and consequently shall have no management or executive powers or functions.  You have the same general legal responsibilities to the Company as any other director.  You will be expected to exercise the general fiduciary duties of care, loyalty, equal treatment of shareholders and confidentiality expected of every director of a Swiss company and further, in accordance with the principles outlined in the Corporate Governance Code, perform your duties faithfully, diligently and to a standard commensurate with the functions of your role and your knowledge, skills and experience.  In particular, as a non-executive director, you are expected to exercise independence on all issues discussed at Board or committee level.

 

3.2                    The Board as a whole is collectively and ultimately responsible for the success of the Company and for delivering sustainable shareholder and stakeholder value.  All directors must take decisions objectively in the interests of the Company.

 

3.3                    You should also refer to and comply with:

 

(a)                       the Articles and the Organisational Regulations (including paragraph 5 which sets out a detailed description of the role of the Board);

 

(b)                       the Listing Rules, the Prospectus Rules, the DTRs and the Admission and Disclosure Standards;

 

(c)                        the Corporate Governance Code and associated Guidance in respect of the role of the Board and the role of the non-executive director;

 

(d)                       the Company’s corporate governance statement as set out in its annual report from time to time; and

 

(e)        directors’ duties under the Swiss CO and the Minder Amendments as well as under any other applicable law.

 

3.4                    As a director you will be required to comply with these duties. In case you are in doubt, you may request information on such duties at any time in accordance with paragraph 3.7 of this letter.

 

3.5                    You have agreed to serve on one or more Board committees. Your role as a member or such Board committees is set out in Annex C of the Organisational Regulations.  [If applicable: You have also accepted and have been appointed to the role of Chairman of the Board (the “Chairman”) by the Company’s shareholders. Your attention is drawn in particular to the Chairman’s duties and responsibilities described in paragraph 5 of the Organisational Regulations and in  the Corporate Governance Code and Guidance.]

 

3

 

3.6                    You further agree that:

 

(a)                       the Board may delegate some of its functions to a sub-committee determined by the Board, and that such sub-committee may make decisions and take actions on behalf of the Company within its terms of reference, if permitted by law and the Articles, without the approval of the full Board and that you may be asked to participate in such other sub-committee of the Board;

 

(b)                       you will attend at Board meetings and give such advice to the Board as is consistent with your duties under applicable law;

 

(c)                        you may be asked, from time to time, to assist an executive director of the Board in a management audit of any Group Company;

 

(d)                       unless specifically authorised to do so by the Board, you shall not enter into any legal or other commitment or contract on behalf of the Company or any Group Company;

 

(e)                        you will abide by your fiduciary duties as a director of the Company. You will immediately report your own wrongdoing or the wrongdoing or proposed wrongdoing of any other employee or director of which you become aware to the Chief Executive Officer or Chairman;

 

(f)                         you will comply with all requirements, recommendations or regulations including the Listing Rules (including the Model Code on directors’ dealings in securities), the DTRs, the Prospectus Rules and the Admission and Disclosure Standards as from time to time amended, the Corporate Governance Code, and all other requirements, recommendations or regulations, as amended from time to time, of the UK Financial Conduct Authority and any other regulatory authority relevant to the Company or any Group Company, including, in particular the New York Stock Exchange and the Athens Exchange, as well as any code or codes as may from time to time be adopted by the Company or any other Group Company on directors’ conduct or dealings in securities of the Company or any Group Company; and

 

(g)                        you will comply with the Company’s anti-corruption and bribery policy and procedures and the UK Bribery Act 2010.

 

3.7                    The Company shall give to you any information concerning the Company as you may reasonably require to enable you to comply with your duties under applicable law as a non-executive director. Any requests for such information should be processed through the Company Secretary.

 

3.8                    If matters arise which cause you concern about your role, you should discuss these matters with the Chairman or Senior Independent Director. If you have any concerns which cannot be resolved, and you choose to resign for that, or any other, reason, you should provide an appropriate written statement to the Chairman or the Senior Independent Director for circulation to the Board.

 

4                              Time Commitment

 

4.1                    You will be expected to devote such time as is necessary for the proper performance of your duties. It is anticipated that you will be required to devote approximately [4] days per month to your role. This will include attendance at approximately 10 Board meetings, AGMs (and EGMs, as the case may be), and meetings with non-executive directors, meetings with shareholders and meetings forming part of the Board evaluation process and updating and training meetings and consideration of all papers prior to such meetings.  Some of these meetings may involve overseas travel. In addition, if you are appointed to any Board committee or take on a specific role such as Chairman or Senior Independent Director it is expected that you will have to attend

 

4

 

additional meetings and have additional responsibilities. Unless urgent and unavoidable circumstances prevent you from doing so, it is expected that you will attend all the meetings outlined in this paragraph.

 

4.2                    The nature of the role makes it impossible to be specific about the maximum time commitment. You may be required to devote additional time to the Company in respect of preparation time and ad hoc matters which may arise and particularly when the Company is undergoing a period of increased activity. At certain times it may be necessary to convene additional Board, committee or shareholder meetings.

 

4.3                    The overall time commitment stated in paragraph 4.1 will increase if you become a committee member or chair, or if you are given additional responsibilities, such as being appointed the Senior Independent Director. Details of the expected increase in time commitment will be covered in any relevant communication confirming the additional responsibility.

 

4.4                    By accepting your appointment you confirm that you are able to commit sufficient time to the role to meet the Company’s expectations. You should obtain the agreement of the Chairman before accepting additional commitments that might affect the time you are able to devote to your role as a non-executive director of the Company.

 

5                              Directors’ Fees and Benefits

 

5.1                    Subject to shareholders’ approval of a sufficient aggregate amount for directors’ remuneration if so required under the Articles and/or the Minder Amendments, the Company (or a designated Group Company, which shall be notified to you) shall pay to you directors’ fees of €65,000 per annum less any deductions or withholdings including tax and/or National Insurance contributions or other social security contributions the Company is required to make.  In addition to the fee referred to above, you will also be entitled to an additional fee less any deductions or withholdings including tax and/or National Insurance contributions or other social security contributions the Company is required to make for your role and/or your membership in one of the Board committees.  The fees shall be payable twice a year in equal instalments. No further fees shall be payable to you unless approved by the Company’s Remuneration Committee (and subject to shareholders’ approval, if applicable). Any fees which are or may be paid will be subject to and in accordance with the Company’s Remuneration Policy from time to time in force.

 

5.2                    The Company (or such designated Group Company) will reimburse you for all reasonable and properly documented expenses you incur in performing the duties of your office.  Such expenses will be paid within 21 days of receipt of an appropriate invoice.

 

5.3                    The Company has directors’ and officers’ liability insurance and it is intended to maintain such cover in relation to the full term of your appointment, subject to the terms and conditions of the policy of insurance from time to time.

 

5.4                    On the termination of your appointment (including any suspension from office in accordance with paragraph 2.3), you will be paid your directors’ fees on a pro-rata basis, to the extent that they are unpaid, up to the date of termination (or suspension).

 

6                              Conflict of Interest and Further Offices

 

6.1                    It is accepted and acknowledged that you have business interests (such as other appointments and shareholdings) other than those in the Company. These have been disclosed to the Company and you have declared any conflicts that are apparent at present.  This includes, in particular, your relationship with Kar-Tess/TCCC. If you become aware of any potential conflicts of interest, these should be disclosed to the Chairman as soon as you become aware of them in accordance with the

 

5

 

Organisational Regulations.  In certain circumstances it may be required under the Organisational Regulations or appropriate for you to exclude yourself from any discussions and/or votes on particular matters in relation to which such conflicts exist or may arise.

 

6.2                    During your appointment you agree to obtain the consent of the Chairman prior to:

 

(a)                       accepting any directorships of publicly quoted companies, or any major external appointments.  The agreement of the Chairman should also be sought before accepting additional commitments that might conflict with your role as a non-executive director of the Company; or

 

(b)                       making any new or further investments (save for any investment resulting in you holding not more than five per cent. of the votes that could be cast at a general meeting of an issuer listed on a recognised stock exchange in an entity which is not a competitor of the Company or any Group Company); or

 

(c)                        accepting any directorship or other role with or making or holding any investment in a Company or other entity which is or is about to be in competition with the Company or any Group Company, except for investments in a scheme or arrangement (including shares in publicly traded mutual funds or investment companies) where the assets of the scheme or arrangement include a multitude of assets and are invested at the discretion of a third party.

 

6.3                    In addition and in accordance with the Organisational Regulations, you must inform the Chairman before accepting any membership of boards of directors or other significant commitments involving affiliation with other businesses or governmental units. Changes to such board memberships or significant commitments must be reported as well.

 

6.4                    In any case, you must not exceed the maximum number of offices permitted by the Articles and the Minder Amendments (once such limits enter into force).

 

7                              Confidentiality

 

7.1                    Subject to any disclosures required by law or any regulatory authority, you shall neither during your appointment nor at any time (without limit) after the cessation thereof, directly or indirectly:

 

(a)                       use for your own purposes or those of any other person, company, business entity or other organisation whatsoever; or

 

(b)                       disclose to any person, company, business entity or other organisation whatsoever;

 

any trade secret or confidential information relating or belonging to the Company or any Group Company including but not limited to any such information relating to any customer, customer list or requirement, price list or pricing structure, sales and marketing information, business plan or dealing, employee or officer, source codes and computer systems, software, financial information and plans, designs, formulae, prototypes, product lines, services, research activities, any document marked ‘Confidential’ (or with a similar expression), or any information which you have been told is confidential or which you might reasonably expect the Company would regard as confidential, or any information which has been given to the Company or any Group Company in confidence by any customer, supplier or other persons.

 

7.2             You shall not at any time during your appointment make any notes or memoranda relating to any matter within the scope of the Company’s business, dealings or affairs otherwise than for the benefit of the Company or any Group Company.

 

6

 

7.3                    The obligations contained in paragraph 7.1 shall cease to apply to any information or knowledge, which may subsequently come into the public domain other than by way of unauthorised disclosure.

 

7.4                    Nothing in this paragraph 7 shall prevent you from disclosing information which you are required or, notwithstanding your duty of confidentiality, entitled to disclose by law, provided that the disclosure is made in accordance with the provisions of that law and you have complied with the Company’s policy from time to time in force regarding such disclosure.

 

7.5                    Your attention is drawn to the requirements under both law and regulation as to the disclosure of inside information, in particular to the DTRs and section 52 of the UK Criminal Justice Act 1993 on insider dealing. You should avoid making any statements that might risk a breach of these requirements. If in doubt, please contact the Chairman or Company Secretary.

 

7.6                    During your period of appointment you are required to comply with the provisions of the Model Code (as annexed to the Listing Rules) in relation to dealing in the Company’s publicly traded or quoted securities, and any such other code as the Company may adopt from time to time which sets out the terms for dealings by directors in the Company’s publicly traded or quoted securities. A copy of the current share dealing code adopted by the Company has been provided to you separately.

 

7.7                    On termination of your appointment with the Company however arising, or at any time at the Board’s request, you shall immediately return to the Company all documents, records, papers or other property belonging to the Company or any Group Company which may be in your possession or under your control, and which relate in any way to the Company’s or a Group Company’s business affairs and you shall not retain any copies thereof.

 

8                              Reasonableness of Restrictions

 

You recognise that during your appointment you will have access to and come into contact with trade secrets and confidential information belonging to the Company or to the Group Companies. You therefore agree that the restrictions contained or referred to in paragraphs 6 and 7 of this letter are reasonable and necessary to protect the legitimate business interests of the Company and the Group Companies both during and after the cessation of your appointment.

 

9                              Review Process and Training

 

The performance of individual directors and the whole Board and its committees is evaluated annually. If, in the interim, there are any matters which cause you concern about your role, you should discuss them with the Chairman as soon as is appropriate. On an on-going basis, and further to the annual evaluation process, the Company will arrange for you to develop and refresh your skills and knowledge in areas which are mutually identified as being likely to be required, or of benefit to you, in carrying out your duties effectively. You should make yourself available for any relevant training sessions which may be organised for the Board.

 

10                       Independent Advice

 

Circumstances may occur when it will be appropriate for you to seek advice from independent advisors at the Company’s expense. The Board’s agreed procedure under which directors may obtain such independent advice can be obtained on request. The Company will reimburse the reasonable cost of expenditure incurred in accordance with the Board’s policy.

 

7

 

11                       Induction

 

Immediately after the commencement of your appointment, the Company provided a full, formal and tailored induction to the Company and the Group Companies.  This included site visits and meetings with senior and middle management and the Company’s auditors as well as an opportunity for major shareholders to meet you.

 

12                       Data Protection and IP

 

12.1             By signing this letter you consent to the Company holding and processing data about you for legal, personnel, administrative and management purposes and in particular to the processing of any personal data (including any sensitive personal data as defined in the Swiss Federal Act on Data Protection) relating to you including, as appropriate:

 

(a)                       information about your physical or mental health or condition in order to monitor sick leave and take decisions as to your fitness to perform your duties; or

 

(b)                       your racial or ethnic origin or religious or similar beliefs in order to monitor compliance with equal opportunities legislation; or

 

(c)                        information relating to any criminal proceedings in which you have been involved for insurance purposes and in order to comply with legal requirements and obligations to third parties.

 

12.2             You consent to the Company making such information available to any of its Group Companies, those who provide products or services to the Company or any Group Companies (such as advisers and payroll administrators), regulatory authorities, potential or future employers, governmental or quasi-governmental organisations and potential purchasers of the Company or the business in which you work.

 

12.3             You also consent to the transfer of such information to the Company’s or any Group Company’s business contacts outside Switzerland in order to further their business interests even where the country or territory in question does not maintain adequate data protection standards.

 

12.4             You shall comply with the Company’s data protection policy, a copy of which is available from the Company Secretary.

 

12.5             The Company may change its data protection policy at any time and will notify you in writing of any changes.

 

12.6             All inventions and designs which you, solely or jointly with others, make or contribute to in the course of providing your services to the Company (whether performing your duties towards the Company or not), as well as all creations, data, findings, works, computer-programs, marks, methods, documents and any other results of your services provided as a director (referred to collectively as: “Results”), belong exclusively to the Company regardless of whether or not Results are protected under applicable laws and regulations. To the extent the Company is not entitled to the rights to Results based on applicable law, you undertake to assign and transfer any rights to and in connection with Results to the Company. The Company is free to modify and use such Results at its own discretion. To the extent legally permissible, you hereby irrevocably waive any moral rights in all works prepared by you in the in the course of providing your services to the Company, to which you are now or may at any future time be entitled under the Swiss Federal Act on Copyright or any similar provisions of law in any jurisdiction, including the right to be identified, the right of integrity and the right against false attribution, and agree not to institute, support, maintain or permit any action or claim to the effect that any treatment, exploitation or use of such works or other materials, infringes your moral rights.

 

8

 

13                       Miscellaneous

 

13.1             The benefit of each undertaking and your obligations in respect of paragraphs 6 to 8 inclusive and paragraph 12.6 may be assigned to and enforced by all successors and assigns for the time being of the Company, and such undertakings and obligations shall operate and remain binding notwithstanding the termination of this letter or your appointment.

 

13.2             This letter cancels and is in substitution for all previous letters of engagement, agreements and arrangements (whether oral or in writing) relating to the subject-matter hereof between you and the Company, all of which shall be deemed to have been terminated by mutual consent. This letter constitutes the entire terms and conditions of your appointment and no waiver or modification of this letter shall be valid unless in writing. For the avoidance of doubt, this paragraph is without prejudice to your election and office as a matter of corporate law and to any of your duties and responsibilities arising out of applicable law or the Articles, the Organisational Regulations or the Company’s other regulations or policies.

 

13.3             You agree that you shall have no remedies in respect of any representation, assurance or warranty (whether made innocently or negligently) that is not set out in this letter and you shall not have any claim for innocent or negligent misrepresentation or negligent misstatement based on any statement in this letter.

 

13.4             The various provisions and sub-provisions of this letter are severable and if any provision or sub-provision is in violation of, or unenforceable under, Swiss law or the applicable law of any jurisdiction where the Company is listed, or if any provision or sub-provision is held to be unenforceable by any court of competent jurisdiction, then such enforceability shall not affect the validity and enforceability of the remaining provisions or sub-provisions in this letter.

 

13.5             No term of this letter is enforceable by a person who is not a party to the contract for services set out in this letter.

 

13.6             This letter is governed by and construed in accordance with the laws of Switzerland. The parties hereto submit to the exclusive jurisdiction of the competent courts at the registered seat of the Company (currently in Steinhausen, Canton of Zug, Switzerland).

 

13.7             All notices to be given under this letter shall be in writing and shall either be delivered personally, sent by email or sent by first class registered post to (in the case of the Company) its registered office or (in your case) your address as set out in this letter or to such address as you specify in writing to the Company.  Notices shall be deemed duly served:

 

(a)                       in the case of a notice delivered personally or by email, at the time of delivery/receipt, and

 

(b)                       in the case of a notice sent by post, two clear business days after the date of despatch.

 

Please indicate your acceptance of these terms by counter-signing the enclosed copy and returning it to Jan Gustavsson.

 

 

Yours sincerely,

 

 

	
 Coca-Cola HBC AG
    	
 
    

 

9

 

	
 Accepted:
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
                            ,   this                                (place, date)
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
Name:
    	
 
    

 

10Exhibit 4.3

 

NEPHROGENEX, INC.

 

AMENDED AND RESTATED

 

INVESTORS’ RIGHTS AGREEMENT

 

February 28, 2008

 

 

TABLE OF CONTENTS

 

	
 
    	
 
    	
Page
    
	
1.
    	
Registration Rights
    	
1
    
	
 
    	
1.1
    	
Definitions
    	
1
    
	
 
    	
1.2
    	
Request for Registration
    	
3
    
	
 
    	
1.3
    	
Company Registration
    	
4
    
	
 
    	
1.4
    	
Form S-3 Registration
    	
6
    
	
 
    	
1.5
    	
Obligations of the Company
    	
7
    
	
 
    	
1.6
    	
Information from Holder
    	
8
    
	
 
    	
1.7
    	
Expenses of Registration
    	
9
    
	
 
    	
1.8
    	
Delay of Registration
    	
9
    
	
 
    	
1.9
    	
Indemnification
    	
9
    
	
 
    	
1.10
    	
Reports Under the 1934 Act
    	
11
    
	
 
    	
1.11
    	
Assignment of Registration Rights
    	
12
    
	
 
    	
1.12
    	
Limitations on Subsequent Registration Rights
    	
12
    
	
 
    	
1.13
    	
“Market Stand-Off” Agreement
    	
12
    
	
 
    	
1.14
    	
Termination of Registration Rights
    	
14
    
	
 
    	
 
    	
 
    	
 
    
	
2.
    	
Covenants of the Company
    	
14
    
	
 
    	
2.1
    	
Delivery of Financial Statements
    	
14
    
	
 
    	
2.2
    	
Inspection
    	
15
    
	
 
    	
2.3
    	
Termination of Information and Inspection Covenants
    	
15
    
	
 
    	
2.4
    	
Right of First Offer
    	
15
    
	
 
    	
2.5
    	
Insurance
    	
17
    
	
 
    	
2.6
    	
Proprietary Information and Inventions Agreements
    	
17
    
	
 
    	
2.7
    	
Employee Agreements
    	
17
    
	
 
    	
2.8
    	
Board Expenses and Committees
    	
17
    
	
 
    	
2.9
    	
Option Plan
    	
18
    
	
 
    	
2.10
    	
Termination of Certain Covenants
    	
18
    
	
 
    	
 
    	
 
    	
 
    
	
3.
    	
Miscellaneous
    	
18
    
	
 
    	
3.1
    	
Successors and Assigns
    	
18
    
	
 
    	
3.2
    	
Governing Law
    	
18
    
	
 
    	
3.3
    	
Counterparts
    	
18
    
	
 
    	
3.4
    	
Titles and Subtitles
    	
19
    
	
 
    	
3.5
    	
Notices
    	
19
    
	
 
    	
3.6
    	
Expenses
    	
19
    
	
 
    	
3.7
    	
Entire Agreement; Amendments and Waivers
    	
19
    
	
 
    	
3.8
    	
Severability
    	
19
    
	
 
    	
3.9
    	
Aggregation of Stock
    	
20
    
	
 
    	
3.10
    	
Additional Investors
    	
20
    

 

i

 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of the 28 day of February, 2008, by and among NEPHROGENEX, INC., a Delaware corporation (the “Company”), and the investors listed on Schedule A hereto, each of which is herein referred to as an “Investor,” and the holders of the Company’s Common Stock listed on Schedule B, each of which is herein referred to as a “Common Holder.”

 

RECITALS

 

WHEREAS, the Company and the Investors are parties to the Series A Preferred Stock Purchase Agreement, dated as of May 4, 2007, as amended by Amendment to Series A Preferred Stock Purchase Agreement, dated December 1, 2007, and as amended and restated on the date hereof (the “Series A Agreement”); and

 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Company’s Series A Preferred Stock and/or shares of Common Stock (“Common Stock”) issued upon conversion thereof (the “Series A Preferred Stock” or “Preferred Stock”) and possess registration rights, information rights, rights of first offer and other rights pursuant to an Investors’ Rights Agreement, dated as of May 4, 2007, by and among the Company, certain holders of Common Stock (the “Common Holders”) and such Existing Investors (the “Prior Agreement”);

 

WHEREAS, the Prior Agreement may be amended, and any provision therein waived prior to the Second Closing (as defined in the Series A Agreement), with the consent of the Company and an Investor Majority (as defined in the Voting Agreement, dated as of May 4 2007, by and among the Company and the Existing Investors) prior to the Second Closing (as defined in the Series A Agreement);

 

WHEREAS, the Existing Investors, as the Investor Majority, desire to amend and restate the Prior Agreement and to accept the rights created pursuant hereto in lieu of the rights granted to them under the Prior Agreement; and

 

WHEREAS, in order to induce certain of the Investors to purchase Series A Preferred Stock and invest funds in the Company pursuant to the Series A Agreement, the Existing Investors, the Common Holders and the Company hereby agree that this Agreement shall govern the rights of the Investors and the Common Holders to cause the Company to register shares of Common Stock issued or issuable to them and certain other matters as set forth herein;

 

NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

 

1.                                      Registration Rights.  The Company covenants and agrees as follows:

 

1.1                               Definitions.  For purposes of this Section 1:

 

 

(a)                                 The term “Act” means the Securities Act of 1933, as amended.

 

(b)                                 The term “BioStratum Stockholder” means a stockholder of BioStratum Incorporated (“BioStratum”) that (i) receives shares of the capital stock of the Company from BioStratum in connection with a dissolution and liquidation of its assets in its entirety (a “BioStratum Dissolution”), (ii) has agreed in writing to be bound by the terms and conditions of this Agreement, the First Refusal and Co-Sale Agreement (as defined in the Series A Agreement) and the Voting Agreement (as defined in the Series A Agreement) and (iii) is not a direct competitor of the Company as reasonably determined by the Company’s Board of Directors.

 

(c)                                  The term “BioStratum Transferees” means each BioStratum Stockholder who (together with any other affiliated BioStratum Stockholders) holds at least three percent (3.0%) of the outstanding capital stock of BioStratum immediately prior to a BioStratum Dissolution.

 

(d)                                 The term “Form S-3” means such form under the Act as in effect on the date hereof or any registration form under the Act subsequently adopted by the SEC that permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC.

 

(e)                                  The term “Holder” means any person owning or having the right to acquire Registrable Securities or any assignee thereof in accordance with Section 1.11 hereof; provided, that the Common Holders shall not be deemed Holders for the purposes of Section 1.2, 1.4, 1.12 and 3.7.

 

(f)                                   The term “Initial Offering” means the Company’s first firm commitment underwritten public offering of its Common Stock under the Act.

 

(g)                                  The term “1934 Act” means the Securities Exchange Act of 1934, as amended.

 

(h)                                 The terms “register,” “registered,” and “registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the Act, and the declaration or ordering of effectiveness of such registration statement or document.

 

(i)                                     The term “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock, (ii) the two hundred ten thousand four hundred seventy-one (210,471) shares of Common Stock issued to the Common Holders; provided, that such shares of Common Stock shall not be deemed Registrable Securities for purposes of Section 1.2, 1.4, 1.12, 2.1, 2.2, 2.4 and 3.7, and (iii) any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange for, or in replacement of, the shares referenced in (i) and (ii) above, excluding in all cases, however, any Registrable Securities sold by a person in a transaction in which his rights under this Section 1 are not assigned.

 

2

 

(j)                                    The number of shares of “Registrable Securities” outstanding shall be determined by the number of shares of Common Stock outstanding that are, and the number of shares of Common Stock issuable pursuant to then exercisable or convertible securities that are, Registrable Securities.

 

(k)                                 The term “Rule 144” shall mean Rule 144 under the Act.

 

(l)                                     The term “Rule 144(k)” shall mean subsection (k) of Rule 144 under the Act.

 

(m)                             The term “SEC” shall mean the Securities and Exchange Commission.

 

1.2                               Request for Registration.

 

(a)                                 Subject to the conditions of this Section 1.2, if the Company shall receive at any time after one hundred eighty (180) days after the effective date of the Initial Offering, a written request from the Holders of the Registrable Securities then outstanding (for purposes of this Section 1.2, the “Initiating Holders”) that the Company file a registration statement under the Act covering the registration of Registrable Securities with an anticipated aggregate offering price of at least $10,000,000, then the Company shall, within twenty (20) days of the receipt thereof, give written notice of such request to all Holders, and subject to the limitations of this Section 1.2, use all commercially reasonable efforts to effect, as soon as practicable, the registration under the Act of all Registrable Securities that the Holders request to be registered in a written request received by the Company within twenty (20) days of the mailing of the Company’s notice pursuant to this Section 1.2(a).

 

(b)                                 If the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 1.2 and the Company shall include such information in the written notice referred to in Section 1.2(a).  In such event the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such Holder) to the extent provided herein.  All Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by a majority in interest of the Initiating Holders (which underwriter or underwriters shall be reasonably acceptable to the Company).  Notwithstanding any other provision of this Section 1.2, if the underwriter advises the Company that marketing factors require a limitation on the number of securities underwritten (including Registrable Securities), then the Company shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of shares that may be included in the underwriting shall be allocated to the Holders of such Registrable Securities pro rata based on the number of Registrable Securities held by all such Holders (including the Initiating Holders).  In no event shall any Registrable Securities be excluded from such underwriting unless all other securities are first excluded.  Any Registrable

 

3

 

Securities excluded or withdrawn from such underwriting shall be withdrawn from the registration.

 

(c)                                  Notwithstanding the foregoing, the Company shall not be required to effect a registration pursuant to this Section 1.2:

 

(i)                                     in any particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting such registration, unless the Company is already subject to service in such jurisdiction and except as may be required under the Act; or

 

(ii)                                  after the Company has effected two (2) registrations pursuant to this Section 1.2, and such registrations have been declared or ordered effective; or

 

(iii)                               during the period starting with the date sixty (60) days prior to the Company’s good faith estimate of the date of the filing of and ending on a date one hundred eighty (180) days following the effective date of a Company-initiated registration subject to Section 1.3 below, provided that the Company is actively employing in good faith all commercially reasonable efforts to cause such registration statement to become effective; or

 

(iv)                              if the Initiating Holders propose to dispose of Registrable Securities that may be registered on Form S-3 pursuant to Section 1.4 hereof; or

 

(v)                                 if the Company shall furnish to Holders requesting a registration statement pursuant to this Section 1.2 a certificate signed by the Company’s Chief Executive Officer or Chairman of the Board stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such registration statement to be effected at such time, in which event the Company shall have the right to defer such filing for a period of not more than ninety (90) days after receipt of the request of the Initiating Holders, provided that such right shall be exercised by the Company not more than once in any twelve (12)-month period and provided further that the Company shall not register any securities for the account of itself or any other stockholder during such ninety (90) day period (other than a registration relating solely to the sale of securities of participants in a Company stock plan, a registration relating to a corporate reorganization or transaction under Rule 145 of the Act, a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities, or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered).

 

1.3                               Company Registration.

 

(a)                                 If (but without any obligation to do so) the Company proposes to register (including for this purpose a registration effected by the Company for stockholders other than the Holders) any of its stock or other securities under the Act in connection with the public offering of such securities (other than a registration relating solely to the sale of securities of participants in a Company stock plan, a registration relating to a corporate reorganization or transaction under Rule 145 of the Act, a registration on any form that

 

4

 

does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities, or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered), the Company shall, at such time, promptly give each Holder written notice of such registration.  Upon the written request of each Holder given within twenty (20) days after mailing of such notice by the Company in accordance with Section 3.5, the Company shall, subject to the provisions of Section 1.3(c), use all commercially reasonable efforts to cause to be registered under the Act all of the Registrable Securities that each such Holder requests to be registered.

 

(b)                                 Right to Terminate Registration.  The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 1.3 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration.  The expenses of such withdrawn registration shall be borne by the Company in accordance with Section 1.7 hereof.

 

(c)                                  Underwriting Requirements.  In connection with any offering involving an underwriting of shares of the Company’s capital stock, the Company shall not be required under this Section 1.3 to include any of the Holders’ securities in such underwriting unless they accept the terms of the underwriting as agreed upon between the Company and the underwriters selected by the Company (or by other persons entitled to select the underwriters) and enter into an underwriting agreement in customary form with such underwriters, and then only in such quantity as the underwriters determine in their sole discretion will not jeopardize the success of the offering by the Company.  If the total amount of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the amount of securities sold other than by the Company that the underwriters determine in their sole discretion is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, that the underwriters determine in their sole discretion will not jeopardize the success of the offering. In no event shall any Registrable Securities be excluded from such offering unless all other stockholders’ securities have been first excluded.  In the event that the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be apportioned pro rata among the selling Holders based on the number of Registrable Securities held by all selling Holders or in such other proportions as shall mutually be agreed to by all such selling Holders.  Notwithstanding the foregoing, in no event shall the amount of securities of the selling Holders included in the offering be reduced below thirty percent (30%) of the total amount of securities included in such offering, unless such offering is the initial public offering of the Company’s securities, in which case the selling Holders may be excluded if the underwriters make the determination described above and no other stockholder’s securities are included in such offering.  For purposes of the preceding sentence concerning apportionment, for any selling stockholder that is a Holder of Registrable Securities and that is a venture capital fund, partnership or corporation, the affiliated venture capital funds, partners, retired partners and stockholders of such Holder, or the estates and family members of any such partners and retired partners and any trusts for the benefit of any of the foregoing persons shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such

 

5

 

“selling Holder” shall be based upon the aggregate amount of Registrable Securities owned by all such related entities and individuals.

 

1.4                               Form S-3 Registration.  In case the Company shall receive from the Holders of Registrable Securities (for purposes of this Section 1.4, the “Initiating Holders”) a written request or requests that the Company effect a registration on Form S-3 and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company shall:

 

(a)                                 promptly give written notice of the proposed registration, and any related qualification or compliance, to all other Holders; and

 

(b)                                 use all commercially reasonable efforts to effect, as soon as practicable, such registration and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company, provided, however, that the Company shall not be obligated to effect any such registration, qualification or compliance, pursuant to this section 1.4:

 

(i)                                     if Form S-3 is not available for such offering by the Holders;

 

(ii)                                  if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public (net of any underwriters’ discounts or commissions) of less than $5,000,000;

 

(iii)                               if the Company shall furnish to Holders requesting a registration statement pursuant to this Section 1.4 a certificate signed by the Company’s Chief Executive Officer or Chairman of the Board stating that in the good faith judgment of the Board of Directors of the Company, it would be seriously detrimental to the Company and its stockholders for such registration statement to be effected at such time, in which event the Company shall have the right to defer such filing for a period of not more than one hundred twenty (120) days after receipt of the request of the Initiating Holders, provided that such right shall be exercised by the Company not more than once in any twelve (12)-month period and provided further that the Company shall not register any securities for the account of itself or any other stockholder during such one hundred twenty (120) day period (other than a registration relating solely to the sale of securities of participants in a Company stock plan, a registration relating to a corporate reorganization or transaction under Rule 145 of the Act, a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities, or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered);

 

6

 

(iv)                              if the Company has, within the twelve (12) month period preceding the date of such request, already effected two (2) registrations on Form S-3 for the Holders pursuant to this Section 1.4; or

 

(v)                                 in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance.

 

(c)                                  If the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 1.4 and the Company shall include such information in the written notice referred to in Section 1.4(a).  The provisions of Section 1.2(b) shall be applicable to such request (with the substitution of Section 1.4 for references to Section 1.2).

 

(d)                                 Subject to the foregoing, the Company shall file a registration statement covering the Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the request or requests of the Initiating Holders.  Registrations effected pursuant to this Section 1.4 shall not be counted as requests for registration effected pursuant to Sections 1.2.

 

1.5                               Obligations of the Company.  Whenever required under this Section 1 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible:

 

(a)                                 prepare and file with the SEC a registration statement with respect to such Registrable Securities and use all commercially reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the Registration Statement has been completed;

 

(b)                                 prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Act with respect to the disposition of all securities covered by such registration statement;

 

(c)                                  furnish to the Holders such number of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them;

 

(d)                                 use all commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions;

 

7

 

(e)                                  in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering;

 

(f)                                   notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing;

 

(g)                                  cause all such Registrable Securities registered pursuant to this Section 1 to be listed on a national exchange or trading system and on each securities exchange and trading system on which similar securities issued by the Company are then listed; and

 

(h)                                 provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration.

 

Notwithstanding the provisions of this Section 1, the Company shall be entitled to postpone or suspend, for a reasonable period of time, the filing, effectiveness or use of, or trading under, any registration statement if the Company shall determine that any such filing or the sale of any securities pursuant to such registration statement would in the good faith judgment of the Board of Directors of the Company:

 

(i)                                     materially impede, delay or interfere with any material pending or proposed financing, acquisition, corporate reorganization or other similar transaction involving the Company for which the Board of Directors of the Company has authorized negotiations;

 

(ii)                                  materially adversely impair the consummation of any pending or proposed material offering or sale of any class of securities by the Company; or

 

(iii)                               require disclosure of material nonpublic information that, if disclosed at such time, would be materially harmful to the interests of the Company and its stockholders; provided, however, that during any such period all executive officers and directors of the Company are also prohibited from selling securities of the Company (or any security of any of the Company’s subsidiaries or affiliates).

 

In the event of the suspension of effectiveness of any registration statement pursuant to this Section 1.5, the applicable time period during which such registration statement is to remain effective shall be extended by that number of days equal to the number of days the effectiveness of such registration statement was suspended.

 

1.6                               Information from Holder.  It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such

 

8

 

information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as shall be reasonably required to effect the registration of such Holder’s Registrable Securities.

 

1.7                               Expenses of Registration.  All expenses other than underwriting discounts and commissions incurred in connection with registrations, filings or qualifications pursuant to Sections 1.2, 1.3 and 1.4, including (without limitation) all registration, filing and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel for the selling Holders shall be borne by the Company.  Notwithstanding the foregoing, the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 1.2 or Section 1.4 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all participating Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless, in the case of a registration requested under Section 1.2, the Holders of a majority of the Registrable Securities agree to forfeit their right to two (2) demand registrations pursuant to Section 1.2 or Section 1.4, as applicable and; provided, however, that if at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness following disclosure by the Company of such material adverse change, then the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Section 1.2 and 1.4.

 

1.8                               Delay of Registration.  No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1.

 

1.9                               Indemnification.  In the event any Registrable Securities are included in a registration statement under this Section 1:

 

(a)                                 To the extent permitted by law, the Company will indemnify and hold harmless each Holder, the partners, officers, directors and stockholders of each Holder, legal counsel and accountants for each Holder, any underwriter (as defined in the Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Act or the 1934 Act, against any losses, claims, damages or liabilities (joint or several) to which they may become subject under the Act, the 1934 Act, any state securities laws or any rule or regulation promulgated under the Act, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a “Violation”):  (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state in such registration statement a material fact required to be stated therein, or necessary to make the statements therein not misleading or (iii) any violation or alleged violation by the Company of the Act, the 1934 Act, any state securities laws or any rule or regulation promulgated under the Act, the 1934 Act or any state securities laws, and the Company will reimburse each such Holder, underwriter, controlling

 

9

 

person or other aforementioned person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action as such expenses are incurred; provided, however, that the indemnity agreement contained in this subsection l.9(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation that occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by any such Holder, underwriter, controlling person or other aforementioned person; provided further, however, that the foregoing indemnity agreement with respect to any preliminary prospectus shall not inure to the benefit of any Holder or underwriter or other aforementioned person, or any person controlling such Holder or underwriter, from whom the person asserting any such losses, claims, damages or liabilities purchased shares in the offering, if a copy of the most current prospectus was not sent or given by or on behalf of such Holder or underwriter or other aforementioned person to such person, if required by law to have been so delivered, at or prior to the written confirmation of the sale of the shares to such person, and if the prospectus (as so amended or supplemented) would have cured the defect giving rise to such loss, claim, damage or liability.

 

(b)                                 To the extent permitted by law, each selling Holder will indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of the Act, legal counsel and accountants for the Company, any underwriter, any other Holder selling securities in such registration statement and any controlling person of any such underwriter or other Holder, against any losses, claims, damages or liabilities (joint or several) to which any of the foregoing persons may become subject, under the Act, the 1934 Act, any state securities laws or any rule or regulation promulgated under the Act, the 1934 Act or any state securities laws, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will reimburse any person intended to be indemnified pursuant to this subsection l.9(b) for any legal or other expenses reasonably incurred by such person in connection with investigating or defending any such loss, claim, damage, liability or action as such expenses are incurred; provided, however, that the indemnity agreement contained in this subsection l.9(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder (which consent shall not be unreasonably withheld), and provided that in no event shall any indemnity under this subsection l.9(b) exceed the net proceeds from the offering received by such Holder.

 

(c)                                  Promptly after receipt by an indemnified party under this Section 1.9 of notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.9, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties;

 

10

 

provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such proceeding.  The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this Section 1.9 to the extent of such prejudice, but the omission to so deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 1.9.

 

(d)                                 If the indemnification provided for in this Section 1.9 is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to herein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and the indemnified party on the other hand in connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense, as well as any other relevant equitable considerations; provided, however, that no contribution by any Holder, when combined with any amounts paid by such Holder pursuant to Section 1.9(b), shall exceed the net proceeds from the offering received by such Holder.  The relative fault of the indemnifying party and the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

 

(e)                                  Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control.

 

(f)                                   The obligations of the Company and Holders under this Section 1.9 shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 1 and otherwise.

 

1.10                        Reports Under the 1934 Act.  With a view to making available to the Holders the benefits of Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company agrees to:

 

(a)                                 make and keep public information available, as those terms are understood and defined in Rule 144, at all times after the effective date of the Initial Offering;

 

11

 

(b)                                 file with the SEC in a timely manner all reports and other documents required of the Company under the Act and the 1934 Act; and

 

(c)                                  furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144 (at any time after ninety (90) days after the effective date of the first registration statement filed by the Company), the Act and the 1934 Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and (iii) such other information as may be reasonably requested to avail any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration or pursuant to such form.

 

1.11                        Assignment of Registration Rights.  The rights to cause the Company to register Registrable Securities pursuant to this Section 1 may be assigned (but only with all related obligations) by a Holder to a transferee or assignee of such securities that (i) is a subsidiary, parent, partner, limited partner, retired partner, member or stockholder of a Holder, or (ii) after such assignment or transfer, holds at least two hundred twenty-five thousand (225,000) shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations or the like after the Recapitalization, provided:  (a) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned; (b) such transferee or assignee agrees in writing to be bound by and subject to the terms and conditions of this Agreement, including, without limitation, the provisions of Section 1.13 below; and (c) such assignment shall be effective only if immediately following such transfer the further disposition of such securities by the transferee or assignee is restricted under the Act.

 

1.12                        Limitations on Subsequent Registration Rights.  From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of at least sixty six and two thirds percent (66-2/3%) of the Registrable Securities, enter into any agreement with any holder or prospective holder of any securities of the Company that would allow such holder or prospective holder (a) to include any of such securities in any registration filed under Section 1.2, Section 1.3 or Section 1.4 hereof, unless under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce the amount of the Registrable Securities of the Holders that are included or (b) to demand registration of their securities.

 

1.13                        “Market Stand-Off” Agreement.

 

(a)                                 Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the Company’s Initial Offering and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (l80) days) (i) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase,

 

12

 

purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock held immediately prior to the effectiveness of the registration statement for such offering, or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash or otherwise.  In addition, if (x) during the last seventeen (17) days of the 180-day restricted period, the Company issues an earnings release or material news or a material event relating to the Company occurs; or (y) prior to the expiration of the one hundred eighty (l80) day restricted period, the Company announces that it will release earnings results during the sixteen (16) day period beginning on the last day of the one hundred eighty (l80) day period, the restrictions imposed by this Section 1.13 shall continue to apply until the expiration of the eighteen (18) day period beginning on the issuance of the earnings release or the occurrence of the material news or material event.  The foregoing provisions of this Section 1.13 shall apply only to the Company’s Initial Offering, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall only be applicable to the Holders if all officers, directors and greater than one percent (1%) stockholders of the Company enter into similar agreements.  The underwriters in connection with the Company’s Initial Offering are intended third-party beneficiaries of this Section 1.13 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto.  Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in the Company’s Initial Offering that are consistent with this Section 1.13 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply to all Holders subject to such agreements pro rata based on the number of shares subject to such agreements.

 

In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to the Registrable Securities of each Holder (and the shares or securities of every other person subject to the foregoing restriction) until the end of such period.

 

(b)                                 Each Holder agrees that a legend reading substantially as follows shall be placed on all certificates representing all Registrable Securities of each Holder (and the shares or securities of every other person subject to the restriction contained in this Section 1.13):

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD OF UP TO 180 DAYS AFTER THE EFFECTIVE DATE OF THE ISSUER’S REGISTRATION STATEMENT FILED UNDER THE ACT, AS AMENDED, AS SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE ORIGINAL HOLDER OF THESE SECURITIES, A COPY OF WHICH MAY BE OBTAINED AT THE ISSUER’S PRINCIPAL OFFICE.  SUCH LOCK-UP PERIOD IS BINDING ON TRANSFEREES OF THESE SHARES.

 

13

 

1.14                        Termination of Registration Rights.  No Holder shall be entitled to exercise any right provided for in this Section 1 (i) after five (5) years following the consummation of the Initial Offering, (ii) as to any Holder, such earlier time after the Initial Offering at which such Holder (A) can sell all shares held by it in compliance with Rule 144(k) or (B) holds one percent (1%) or less of the Company’s outstanding Common Stock and all Registrable Securities held by such Holder (together with any affiliate of the Holder with whom such Holder must aggregate its sales under Rule 144) can be sold in any three (3)-month period without registration in compliance with Rule 144 or (iii) after the consummation of a Liquidation Event, as that term is defined in the Company’s Restated Certificate of Incorporation, as in effect from time to time (the “Restated Certificate”).

 

2.                                      Covenants of the Company.

 

2.1                               Delivery of Financial Statements.  The Company shall, upon request, deliver to each Investor (or transferee of an Investor) that holds at least eight hundred forty-six thousand eight hundred thirty-five (846,835) shares of Registrable Securities and each of BioStratum Incorporated (or, in the event of a BioStratum Dissolution, the BioStratum Transferees) and Vanderbilt University (“Vanderbilt”) so long as, respectively, BioStratum Incorporated (or the BioStratum Transferees as a collective) continue to hold at least fifty percent (50%) of the shares of the capital stock of the Company held by BioStratum as of the date hereof and Vanderbilt continues to hold at least fifty percent (50%) of the shares of capital stock held by Vanderbilt as of the date hereof (each as equitably adjusted for stock splits, stock dividends, combinations, recapitalizations, and the like after the Recapitalization (as defined in the Restated Certificate)) (each, a “Major Investor”):

 

(a)                                 as soon as practicable, but in any event within ninety (90) days after the end of each fiscal year of the Company, an income statement for such fiscal year, a balance sheet of the Company and statement of stockholders’ equity as of the end of such year, and a statement of cash flows for such year, such year-end financial reports to be in reasonable detail, prepared in accordance with generally accepted accounting principles (“GAAP”), and audited and certified by independent public accountants of nationally recognized standing selected by the Company;

 

(b)                                 as soon as practicable, but in any event within thirty (30) days after the end of each of the first three (3) quarters of each fiscal year of the Company, an unaudited income statement, statement of cash flows for such fiscal quarter and an unaudited balance sheet as of the end of such fiscal quarter;

 

(c)                                  within twenty (20) days of the end of each month, an unaudited income statement and statement of cash flows and balance sheet for and as of the end of such month, in reasonable detail;

 

(d)                                 as soon as practicable, but in any event at least thirty (30) days prior to the end of each fiscal year, a budget and business plan for the next fiscal year, prepared on a monthly basis, including balance sheets, income statements and statements of cash flows for such months and, as soon as prepared, any other budgets or revised budgets prepared by the Company;

 

14

 

(e)                                  with respect to the financial statements called for in subsections (b) and (c) of this Section 2.1, an instrument executed by the Chief Financial Officer or President of the Company certifying that such financials were prepared in accordance with GAAP consistently applied with prior practice for earlier periods (with the exception of footnotes that may be required by GAAP) and fairly present the financial condition of the Company and its results of operation for the period specified, subject to year-end audit adjustment; and

 

(f)                                   such other information relating to the financial condition, business or corporate affairs of the Company as the Major Investor may from time to time request, provided, however, that the Company shall not be obligated under this subsection (f) or any other subsection of Section 2.1 to provide information that it deems in good faith to be a trade secret or similar confidential information.

 

2.2                               Inspection.  The Company shall permit each New Investor (as defined in the Series A Agreement), at such New Investor’s expense, to visit and inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be requested by the New Investor; provided, however, that the Company shall not be obligated pursuant to this Section 2.2 to provide access to any information that it reasonably considers to be a trade secret or similar confidential information.

 

2.3                               Termination of Information and Inspection Covenants.  The covenants set forth in Sections 2.1 and 2.2 shall terminate and be of no further force or effect upon the earlier to occur of (i) the consummation of the sale of securities pursuant to a registration statement filed by the Company under the Act in connection with the firm commitment underwritten offering of its securities to the general public, (ii) when the Company first becomes subject to the periodic reporting requirements of Sections 12(g) or 15(d) of the 1934 Act, whichever event shall first occur or (iii) the consummation of a Liquidation Event.

 

2.4                               Right of First Offer.  Subject to the terms and conditions specified in this Section 2.4, the Company hereby grants to each Major Investor a right of first offer with respect to future sales by the Company of its Shares (as hereinafter defined).  For purposes of this Section 2.4, the term “Major Investor” includes any general partners, members, stockholders and affiliates of a Major Investor.  A Major Investor shall be entitled to apportion the right of first offer hereby granted it among itself and its partners, members, stockholders and affiliates in such proportions as it deems appropriate.

 

Each time the Company proposes to offer any shares of, or securities convertible into or exchangeable or exercisable for any shares of, its capital stock (“Shares”), the Company shall first make an offering of such Shares to each Major Investor in accordance with the following provisions:

 

(a)                                 The Company shall deliver a notice in accordance with Section 3.5 (“Notice”) to the Major Investors stating (i) its bona fide intention to offer such Shares, (ii) the number of such Shares to be offered and (iii) the price and terms upon which it proposes to offer such Shares.

 

15

 

(b)                                 By written notification received by the Company within twenty (20) calendar days after the giving of Notice, each Major Investor may elect to purchase, at the price and on the terms specified in the Notice, up to that portion of such Shares that equals the proportion that the number of shares of Common Stock that are Registrable Securities issued and held by such Major Investor (assuming full conversion and exercise of all convertible and exercisable securities then outstanding) bears to the number of shares of Common Stock of the Company then outstanding (assuming full conversion and exercise of all convertible and exercisable securities then outstanding).  The Company shall promptly, in writing, inform each Major Investor that elects to purchase all the shares available to it (a “Fully-Exercising Investor”) of any other Major Investor’s failure to do likewise.  During the ten (10) day period commencing after such information is given, each Fully-Exercising Investor may elect to purchase that portion of the Shares for which Major Investors were entitled to subscribe, but which were not subscribed for by the Major Investors, that is equal to the proportion that the number of shares of Registrable Securities issued and held by such Fully-Exercising Investor bears to the total number of shares of Registrable Securities held by all Fully-Exercising Investors.

 

(c)                                  If all Shares that Major Investors are entitled to obtain pursuant to subsection 2.4(b) are not elected to be obtained as provided in subsection 2.4(b) hereof, the Company may, during the ninety (90) day period following the expiration of the period provided in subsection 2.4(b) hereof, offer the remaining unsubscribed portion of such Shares to any person or persons at a price not less than that, and upon terms no more favorable to the offeree than those, specified in the Notice.  If the Company does not enter into an agreement for the sale of the Shares within such period, or if such agreement is not consummated within sixty (60) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such Shares shall not be offered unless first reoffered to the Major Investors in accordance herewith.

 

(d)                                 The right of first offer in this Section 2.4 shall not be applicable to (i) the issuance or sale of shares of Common Stock (or options therefor) to employees, directors, consultants and other service providers for the primary purpose of soliciting or retaining their services pursuant to plans or agreements approved by the Company’s Board of Directors, (ii) the issuance of securities pursuant to a bona fide, firmly underwritten public offering of shares of Common Stock registered under the Act, at an offering price of at least $3.33 per share (appropriately adjusted for any stock split, dividend, combination or other recapitalization occurring) and resulting in proceeds to the Company of at least $30,000,000 in the aggregate, (iii) the issuance of securities pursuant to the conversion or exercise of convertible or exercisable securities, (iv) the issuance of securities in connection with a bona fide business acquisition by the Company of a bona fide commercial operating entity, whether by merger, consolidation, sale of assets, sale or exchange of stock or otherwise, (v) the issuance and sale of Series A Preferred Stock pursuant to the Series A Agreement, (vi) the issuance of stock, warrants or other securities or rights to persons or entities with which the Company has strategic licensing relationships, provided such issuances are primarily for other than equity financing purposes, (vii) Common Stock issued or deemed issued pursuant to subsection 4(d)(i)(E) of Article IV of the Restated Certificate or (viii) Common Stock issued to persons or entities pursuant to commercial debt facilities, provided such issuances are for other than primarily equity financing purposes.  In addition to the foregoing, the right of first offer in this Section 2.4 shall not be applicable with respect to any Major Investor in any subsequent offering of Shares if (i) at the

 

16

 

time of such offering, the Major Investor is not an “accredited investor,” as that term is then defined in Rule 501(a) of the Act and (ii) such offering of Shares is otherwise being offered only to accredited investors.

 

(e)                                  The rights provided in this Section 2.4 may not be assigned or transferred by any Major Investor; provided, however, that a Major Investor that is a venture capital fund may assign or transfer such rights to an affiliated venture capital fund.

 

(f)                                   The covenants set forth in this Section 2.4 shall terminate and be of no further force or effect upon the consummation of (i) the Company’s sale of its Common Stock or other securities pursuant to Registration Statement under the Act, at an offering price of at least $3.33 per share (appropriately adjusted for any stock split, dividend, combination or the like after the Recapitalization) and resulting in proceeds to the Company of at least $30,000,000 in the aggregate (other than a registration statement relating either to the sale of securities to employees of the Company pursuant to its stock option, stock purchase or similar plan or a SEC Rule 145 transaction) or (ii) a Liquidation Event, as that term is defined in the Restated Certificate.

 

2.5                               Insurance.  The Company has as of the date hereof or shall within thirty (30) days of the First Closing (as defined in the Series A Agreement”) obtain and maintain from financially sound and reputable insurers (a) term life insurance on the life of J. Wes Fox, which shall provide for coverage and other terms mutually acceptable to the Company and the Investors, name the Company as loss payee and not be cancelable by the Company without prior approval of the Board of Directors and (b) directors and officers insurance, which shall provide for coverage of each director of at least five million dollars ($5,000,000) and such other terms mutually acceptable to the Company and the Investors.

 

2.6                               Proprietary Information and Inventions Agreements.  The Company shall require all employees and consultants with access to confidential information to execute and deliver a Proprietary Information and Inventions Agreement in substantially the form approved by the Company’s Board of Directors.

 

2.7                               Employee Agreements.  Unless approved by the Compensation Committee of the Board of Directors of the Company, all future employees of the Company who shall purchase, or receive options to purchase, shares of the Company’s Common Stock following the date hereof shall be required to execute stock purchase or option agreements providing for (i) vesting of shares over a four-year period with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or services, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months thereafter and (ii) a one hundred eighty (180) day lockup period in connection with the Company’s initial public offering.  The Company shall retain a right of first refusal on transfers until the Company’s initial public offering and the right to repurchase unvested shares at cost.

 

2.8                               Board Expenses and Committees.  The Company shall reimburse the reasonable expenses, including domestic first-class travel expenses, of non-employee directors incurred in connection with attending meetings of the Company’s Board of Directors or

 

17

 

any committees thereof.  Each of Care Capital Investments III, LP and Capital Offshore Investments III, LP (the “Care Capital Entities”), on the one hand, and Rho Ventures V, LP and Rho Ventures V Affiliates, LLC (the “Rho Entities”), on the other hand, shall have the right to have one (1) of the members of the Company’s Board of Directors that the Care Capital Entities or the Rho Entities, as the case may be, nominate pursuant to Section 3(b) of that certain Amended and Restated Voting Agreement, dated February 28, 2008, by and among the Company, the Care Capital Entities and certain other of the Company’s stockholders (the “Voting Agreement”) be appointed to each committee or subcommittee of the Company’s Board of Directors.

 

2.9                               Option Plan.  The Company covenants and agrees that no more than nine hundred four thousand eight hundred eighty-eight (904,888) shares of the Common Stock (or options or other rights exercisable therefore) (as equitably adjusted for stock splits, stock dividends, combinations or the like after the Recapitalization) shall be issued or granted pursuant to the Company’s stock option plan or equity incentive plans, whether or not currently existing, prior to the Second Closing (as defined in the Series A Agreement).

 

2.10                        Termination of Certain Covenants.  The covenants set forth in Sections 2.5, 2.6, 2.7, 2.8, 2.9 shall terminate and be of no further force or effect upon the consummation of (i) the Company’s sale of its Common Stock or other securities pursuant to Registration Statement under the Act, at an offering price of at least $3.33 per share (appropriately adjusted for any stock split, dividend, combination or the like after the Recapitalization) and resulting in proceeds to the Company of at least $30,000,000 in the aggregate (other than a registration statement relating either to the sale of securities to employees of the Company pursuant to its stock option, stock purchase or similar plan or a SEC Rule 145 transaction) or (ii) a Liquidation Event.

 

3.                                      Miscellaneous.

 

3.1                               Successors and Assigns.  Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any shares of Registrable Securities).  Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

3.2                               Governing Law.  This Agreement shall be governed by and construed under the laws of the State of North Carolina as applied to agreements among North Carolina residents entered into and to be performed entirely within North Carolina.

 

3.3                               Counterparts.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

18

 

3.4                               Titles and Subtitles.  The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

 

3.5                               Notices.  All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed effectively given:  (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.  All communications shall be sent to the respective parties at the addresses set forth on the signature pages attached hereto (or at such other addresses as shall be specified by notice given in accordance with this Section 3.5).

 

3.6                               Expenses.  If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled.

 

3.7                               Entire Agreement; Amendments and Waivers.  This Agreement (including the Exhibits hereto, if any) constitutes the full and entire understanding and agreement among the parties with regard to the subjects hereof and thereof.  Any term of this Agreement (other than Section 2.1, Section 2.2, Section 2.3 and Section 2.4) may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and (A) an Investor Majority (as defined in the Voting Agreement) prior to the Second Closing or (B) the holders of at least sixty six and two thirds percent (66-23%) of the Registrable Securities on or after the Second Closing.  The provisions of Section 2.1, Section 2.2, Section 2.3 and Section 2.4 may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the holders of at least sixty six and two thirds percent (66-2/3%) of the Registrable Securities that are held by Major Investors.  In addition to the foregoing, (i) the provisions of Section 1.1(b) and the portion of Section 2.1 relating expressly to BioStratum may be amended and the observance of any term thereof may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of BioStratum (or, in the event of a BioStratum Dissolution, by the BioStratum Transferees holding at least a majority of the Company’s capital stock held by all BioStratum Transferees) and (ii) the portions of Section 2.1 relating expressly to Vanderbilt may be amended and the observance of any term thereof may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of Vanderbilt.  Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Registrable Securities, each future holder of all such Registrable Securities, and the Company. The Prior Agreement is hereby amended and restated in its entirety and shall be of no further force or effect.

 

3.8                               Severability.  If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision(s) shall be excluded from this

 

19

 

Agreement and the balance of the Agreement shall be interpreted as if such provision(s) were so excluded and shall be enforceable in accordance with its terms.

 

3.9                               Aggregation of Stock.  All shares of Registrable Securities held or acquired by affiliated entities (including affiliated venture capital funds) or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement.

 

3.10                        Additional Investors.  Notwithstanding Section 3.7, no consent shall be necessary to add additional Investors as signatories to this Agreement, provided that such Investors have purchased Series A Preferred Stock pursuant to the subsequent closing provisions of Section 1.3 of the Series A Agreement.

 

20

 

IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

	
 
    	
 
    	
COMPANY
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
NEPHROGENEX, INC.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   J. Wesley Fox
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Name:
    	
J.   Wesley Fox
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Title:
    	
President   and CEO
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
Address:
    	
204   Cherwell Dr
    
	
 
    	
 
    	
Cary,   NC 27513
    

 

SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
 FOR NEPHROGENEX, INC.

 

 

IN WITNESS WHEREOF, the parties have executed this Investors’ Rights Agreement as of the date first above written.

 

	
 
    	
 
    	
INVESTORS   AND/OR COMMON
   HOLDERS:
    
	
 
    	
 
    	
 
    
	
 
    	
 
    
	
 
    	
CARE   CAPITAL INVESTMENTS III, LP
    
	
 
    	
CARE   CAPITAL OFFSHORE INVESTMENTS III, LP
    
	
 
    	
 
    	
 
    
	
 
    	
By:   CARE CAPITAL LLC, their General Partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   David R. Ramsey
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Name:
    	
David   R. Ramsey
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
Title:
    	
Partner
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
Address:
    	
 
    
	
 
    	
 
    	
 
    

 

SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
 FOR NEPHROGENEX, INC.

 

 

IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’ Rights Agreement as of the date first above written.

 

	
 
    	
 
    	
INVESTORS   AND/OR COMMON
   HOLDERS:
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    
	
 
    	
RHO   VENTURES V, L.P.
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   RMV V, L.L.C., its General Partner
    
	
 
    	
By:   Rho Capital Partners LLC, its Managing Member
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Jeffrey I. Martin
    
	
 
    	
 
    	
 
    	
Name:
    	
Jeffrey   I. Martin
    
	
 
    	
 
    	
 
    	
Title:
    	
Attorney-In-Fact
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
RHO   VENTURES V AFFILIATES, L.L.C.
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
By:   RMV V, L.L.C., its General Partner
    
	
 
    	
By:   Rho Capital Partners LLC, its Managing Member
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Jeffrey I. Martin
    
	
 
    	
 
    	
 
    	
Name:
    	
Jeffrey   I. Martin
    
	
 
    	
 
    	
 
    	
Title:
    	
Attorney-In-   Fact
    
								

 

SIGNATURE PAGE TO AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
 FOR NEPHROGENEX, INC.

 

 

NEPHROGENEX, INC.

 

STOCKHOLDERS’ CONSENT

 

This Consent, effective as of February 14, 2014, is delivered pursuant to the terms of the Amended and Restated Investors’ Rights Agreement among NephroGenex, Inc., a Delaware corporation (the “Corporation”) and the investors named therein (the “Investors’ Rights Agreement”). Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in the Investors’ Rights Agreement.

 

WHEREAS, Section 3.7 of the Investors’ Rights Agreement provides that any term of the Investors’ Rights Agreement (other than Section 2.1, Section 2.2, Section 2.3 and Section 2.4) may be amended and the observance of any term of the Investors’ Rights Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Corporation and the holders of at least sixty six and two thirds percent (66-2/3%) of the Registrable Securities.

 

WHEREAS, Section 3.7 of the Investors’ Rights Agreement provides that Section 2.1, Section 2.2, Section 2.3 and Section 2.4 may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Corporation the holders of at least sixty six and two thirds percent (66-2/3%) of the Registrable Securities that are held by Major Investors.

 

WHEREAS, Section 3.7 of the Investors’ Rights Agreement additionally provides that any amendment or waiver effected in accordance with Section 3.7 shall be binding upon each holder of any Registrable Securities, each future holder of all such Registrable Securities, and the Company.

 

NOW THEREFORE, the Corporation and the undersigned stockholders of the Corporation, who hold at least sixty six and two thirds percent (66-2/3%) of the Registrable Securities hereby agree to amend, waive and terminate Sections 2.5, 2.6, 2.7, 2.8 and 2.9 of the Investors’ Rights Agreement, such that Sections 2.5, 2.6, 2.7, 2.8 and 2.9 shall have no further force and effect.

 

In addition, the Corporation and the undersigned stockholders of the Corporation, who hold at least sixty six and two thirds percent (66-2/3%) of the Registrable Securities that are held by Major Investors hereby agree to amend, waive and terminate Section 2.4 of the Investors’ Rights Agreement, such that Section 2.4 shall have no further force and effect.

 

This consent may be executed in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

 

 

IN WITNESS WHEREOF, this Stockholders’ Consent has been executed as of the latest date set forth below.

 

[Signature Pages Follow]

 

 

	
Dated:   February 20, 2014
    	
COMPANY:
    
	
 
    	
 
    
	
 
    	
NEPHROGENEX, INC.
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Pierre Legault
    
	
 
    	
 
    	
Name:
    	
Pierre   Legault
    
	
 
    	
 
    	
Title:
    	
CEO
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
INVESTORS:
    
	
 
    	
 
    
	
Dated:   February 20, 2014
    	
CARE   CAPITAL INVESTMENTS III, LP
    
	
 
    	
CARE   CAPITAL OFFSHORE INVESTMENTS III, LP
    
	
 
    	
 
    
	
 
    	
By:   CARE CAPITAL LLC, their General Partner
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Richard J. Markham
    
	
 
    	
 
    	
Name:
    	
Richard   J. Markham
    
	
 
    	
 
    	
Title:
    	
Partner
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Dated:   February 19, 2014
    	
RHO   VENTURES V, L.P.
    
	
 
    	
RHO   VENTURES V AFFILIATES, L.L.C.
    
	
 
    	
 
    
	
 
    	
By:   RMV V, L.L.C., its General Partner
    
	
 
    	
By:   Rho Capital Partners LLC, its Managing Member
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Jeffrey Martin
    
	
 
    	
 
    	
Name:
    	
Jeffrey   Martin
    
	
 
    	
 
    	
Title:
    	
Attorney-in-fact
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
Dated:   February 14, 2014
    	
BIOSTRATUM, INCORPORATED
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Eugen Steiner
    
	
 
    	
 
    	
Name:
    	
Eugen   Steiner
    
	
 
    	
 
    	
Title:
    	
Chairman

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00228-of-00352.parquet"}]]